Shots::stosohSthShots:

• Almac to receive upfront- research funding- development and commercial milestones along with the royalties on sales of products emerging from the collaboration. MSD will be responsible for conducting lead optimization- pre/clinical development and commercialization
• The collaboration will utilize Almac’s unique Ubi-Plex platform to identify and develop novel inhibitors against specified DUBs and will initially focus on neurodegenerative diseases
• Almac’s Ubi-Plex platform offers the opportunity to generate novel- innovative candidate drugs targeting multiple therapeutic areas including oncology- viral- inflammatory and metabolic disorders

Click here ­to­ read full press release/ article | Ref: Almac | Image: GMP News